• 동의생리병리학회지
• /
• 제16권3호
• /
• pp.572-576
• /
• 2002

Banhasasim-tang(半夏瀉心湯), oriental medicine, has been used for the treatment of the gastric diseases and cimetidine, H2-receptor blocker, has been also used as the gastric ulcer remedy but has some side action. Therefore the concurrent administration of these two drugs may increase antiulcer activities and also decrease cimetidine's side action more than administrating one by one. In order to investigate antiulcer activities, some experiments were conducted. The concurrent administration of Banhasasim-tang extract(BS) and cimetidine(CM) given intraperitoneally (CM 50mg/kg + BS 300mg/kg and CM 50mg/kg + BS 500 mg/kg), significantly inhibited Shay, aspirin and indomethacin ulcers in rats.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권15호
• /
• pp.6595-6597
• /
• 2015

Objective: To investigate short- and long-term treatment effects and side reactions of lobaplatin plus 5-Fu combined and concurrent radiotherapy in treating patients with inoperable middle-advanced stage esophageal cancer. Methods: Sixty patients with middle-advanced stage esophageal squamous cell cancer were retrospectively analyzed. All patients were administered lobaplatin (50 mg intravenously) for 2 h on day 1, and 5-Fu ($500mg/m^2$) injected intravenously from day 1 to 5 for 1 cycle, in an interval of 21 days for totally 4 cycles. At the same time, late-course accelerated hyperfractionated three-dimensional conformal radiotherapy was performed. Patients were firstly treated with conventional fractionated irradiation (1.8 Gy/d, 5 times/week, a total of 23 treatments, and DT41.4 Gy), and then treated with accelerated hyperfractionated irradiation (1.5 Gy, 2 times/d, a total of 27 Gy in 9 days, an entire course of 6-7 weeks, and DT 68.4Gy). Results: All patients completed treatment, including 10 complete response (CR), 41 partial response (PR), 7 stable disease (SD), and 2 progressive disease (PD). The total effective rate was 85.0% (51/60). Thirty-nine patients had an increased KPS score. One-, 2-, and 3-year survival rates were 85.3%, 57.5%, and 41.7%, respectively. The median survival time was 27 months. The adverse reactions included myelosuppression, which was mainly degree I and II. The occurrence rate of radiation esophagitis was 17.5%. No significant hepatic or renal toxicity was observed. Conclusion: Lobaplatin plus 5-Fu combined with concurrent radiotherapy is safe and effective in treating patients with middle-advanced stage esophageal cancer. However, this result warrants further evaluation by randomized clinical studies.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권12호
• /
• pp.4825-4832
• /
• 2015

Incidence rates of nasopharyngeal carcinoma are high in Indonesia, Singapore and South-Eastern China. Chemoradiotherapy has been the standard regimen for locally advanced nasopharyngeal carcinoma according to guidelines from the National Comprehensive Cancer Network. Recently, advances in the management of nasopharyngeal carcinoma have transferred into better treatment outcomes. Most phase III clinical trials support the addition of concurrent chemotherapy to radiotherapy for the initial treatment of these patients. Studies evaluating effects and toxicity of concurrent chemotherapy with different regimens have been reported. However, the status of adding adjuvant chemotherapy or induction chemotherapy remains controversial. Recent studies have shown that adjuvant chemotherapy with two or three cycles may improve survival for nasopharyngeal carcinoma with stage N2-3 disease or with persistently detectable plasma EBV DNA after radiotherapy. This review examines the pertinent issues and latest studies concerning the management of loco-regionally advanced NPC, regarding concurrent chemotherapy, adjuvant chemotherapy, and induction chemotherapy in decades.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권2호
• /
• pp.899-904
• /
• 2014

Concurrent chemo-radiation (CRT) has been established as the standard of care for non-metastatic loco-regionally advanced nasopharyngeal carcinoma (NPC) but recently the addition of induction chemotherapy in the already established regimen has presented an attractive multidisciplinary approach. This retrospective study was carried out to evaluate the efficacy of induction chemotherapy (IC) followed by CRT for the management of loco-regionally advanced NPC. Between July 2005 and September 2010, 99 patients were treated with cisplatin based IC followed by CRT. Induction chemotherapy included a 2 drug combination; intravenous gemcitabine $1000mg/m^2$ on day 1 and 8 and cisplatin $75mg/m^2$ on day 1 only. Radiotherapy (RT) was given as a phase treatment to a total dose of 70 Gy in 35 fractions. Concurrent cisplatin ($75mg/m^2$) was administered to all patients on days 1, 22 and 43. All patients were evaluated for tumor response and adverse effects after IC and 6 weeks after the completion of the treatment protocol. Statistical analysis was performed using SPSS version 17 and Kaplan Meier estimates were applied to project survival. Median follow-up duration was 20 months. The 5-year overall survival (OS), loco regional control (LRC) and relapse free survival (RFS) rates were 71%, 73% and 50%respectively. Acute grade 4 toxicity related to induction chemotherapy and concurrent chemo-radiation was 4% and 2% respectively, with only 3 toxicity-related hospital admissions. We conclude that induction gemcitabine and cisplatin followed by chemo-radiation is a safe and effective regimen in management of nasopharyngeal carcinoma, meriting further investigation in randomized clinical trials.

• 대한한방소아과학회지
• /
• 제26권3호
• /
• pp.20-29
• /
• 2012

Objectives The purpose of this case study is to report the effect of concurrent administration of Danguieumja-gagambang and external treatments on childhood psoriasis. Methods The subject is a child with psoriasis. This patient was treated with oriental herbal medicine (Danguieumjagagambang) and external treatments. The improvement of the skin condition is observed by Psoriasis Area and Severity Index (PASI) score. Results After the treatment, the symptoms of psoriasis were relieved. PASI score of this child went down from 4.7 to 0. Conclusions This study showed that concurrent administration of Danguieumja-gagambang and external treatments can be an effective choice for psoriasis.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권8호
• /
• pp.3945-3951
• /
• 2016

Background: Whether concurrent chemotherapy treatment is superior to radiotherapy alone as an adjuvant regimen for postoperative cervical carcinoma with risk factors remains controversial. Materials and Methods: A literature search strategy examined Pubmed, Embase, the Cochrane Library, the China National Knowledge Internet Web, the Chinese Biomedical Database and the Wanfang Database. Article reference lists and scientific meeting abstracts were also screened. Controlled trials comparing concurrent chemoradiotherapy versus radiotherapy alone in postoperative cervical cancer were included. The methodological quality of non-randomized controlled trials was evaluated using the Newcastle-Ottawa Scale. Randomized controlled studies were evaluated with the Cochrane handbook. A meta-analysis was performed with RevMan 5.3. Results: A total of 1,073 patients from 11 clinical trials were analysed, with 582 patients in the concurrent chemoradiotherapy group and 491 patients in the radiotherapy group. Hazard ratios (HR) of 0.47 (95% CI 0.31-0.72) and 0.50 (95% CI 0.35-0.72) were observed for overall survival and progression-free survival, indicating a benefit from the additional use of concurrent chemotherapy. Subgroup analyses demonstrated that cervical cancer with high risk factors significantly benefitted from concurrent chemotherapy when examining overall survival (HR 0.44, 95% CI 0.28-0.67) and progression-free survival (HR 0.48, 95% CI 0.33-0.70), but patients with intermediate risk factors showed no benefit from concurrent chemotherapy in overall survival (HR 1.72, 95% CI 0.28-10.41) and progression-free survival (HR 1.09, 95% CI 0.19-6.14). No significant differences were observed for grade 3-4 anaemia (risk ratio (RR) 3.87, 95% CI 0.69-21.84), grade 3-4 thrombocytopenia (RR 3.04, 95% CI 0.88-10.58), grade 3-4 vomiting or nausea (RR 1.71, 95% CI 0.27-10.96), or grade 3-4 diarrhoea (RR 1.40, 95% CI 0.69-2.83). Significant differences were observed for grade 3-4 neutropenia in favour of the radiotherapy group (RR 7.23, 95% CI 3.94-13.26). Conclusions: In conclusion, concurrent chemoradiotherapy improves survival in postoperative cervical cancer with high risk factors but not in those with intermediate risk factors.

• 대한한방내과학회지
• /
• 제40권4호
• /
• pp.697-708
• /
• 2019

Objective: The aim of this study was to introduce gastric dysmotility as a common cause in patients with concurrent functional dyspepsia and chronic atrophic gastritis. Method: Dyspeptic symptoms, the Rydoraku score, gastric motility (electrogastrography, bowel sound analysis), gastric mucosa (gastroendoscopy), and blood and blood chemistry were all evaluated. For the treatment method, Pyengwi-san (solution) and Banwhasashim-tang (extract) were used as herbal drugs. Both ST36 electrical stimulation and simple immersion stimulation of CV11, 12, and 13 in the abdomen were applied. Results: Dyspeptic symptoms including indigestion, headache, and insomnia were all relieved. Gastric myoelectrical activity and gastric pyloric function were additionally improved. The condition of the gastric mucosa was changed from atrophic to erosive. Other side-effects of the treatment were not noted. Conclusion: The traditional Korean treatment showed effectiveness in the relief of dyspeptic symptoms and mucosal improvement of chronic atrophic gastritis. Gastric dysmotility is a common cause of the condition being concurrent with both functional dyspepsia and chronic atrophic gastritis without Helicobacter pylori infection.

• Radiation Oncology Journal
• /
• 제26권3호
• /
• pp.160-165
• /
• 2008

목 적: 국소 진행성 폐암에서 동시 항암화학 방사선 요법이 표준 요법으로 자리 잡고 있다. 그러나 항암제의 그 사용시기와 방법에 있어서는 확립된 바가 없어서 gemcitabine, cisplatin 병용화학요법과 동시 방사선치료의 치료효과 및 안전성을 확인하였다. 대상 및 방법: 동시 항암화학 방사선요법시 gemcitabine $500\;mg/m^2$, cisplatin $30\;mg/m^2$ 요법은 2주 간격으로 환자의 순응도에 따른 방사선치료 기간의 변동을 감안해서 $3{\sim}4$회 치료하는 것을 원칙으로 하였고 흉부방사선치료는 1일 1회 1.8 Gy 씩, 주5회 분할조사 하였으며, 원발병소와 종격동 및 전이를 나타낸 림프절을 포함한 부분에 50.4 Gy를 조사 후 질환이 진행되지 않았을 경우 원발 병소에 18 Gy를 추가 조사하였다. 공고 화학요법은 3주 간격으로 $2{\sim}3$회 치료하였다. 치료반응의 판정은 동시 항암화학 방사선요법 후와 공고 화학요법 후에 각각 WHO의 판정기준에 따라 평가했다. 결 과: 29명의 대상 중, 동시 항암화학 방사선요법 후 완전관해는 1명(4%), 부분 관해는 20명(69%)이었고 공고 화학요법이 마친 후 치료 판정에서 완전 관해는 3명(10%), 부분 관해는 21명(72%)이였다. 중앙 생존 기간은 16개월($2.4{\sim}39.2$개월)이고 1년 생존율은 62.7%, 2년 생존율은 43.9%, 3년 생존율은 20%이었다. 치료 도중 독성의 빈도는 3도 이상의 과립구 감소증이 11명(37.9%)이었고 3도 이상의 식도염이 15명(51.7%)이 발생하였다. 2도 이상의 폐렴은 6명(20.7%)에서 발생하였다. 결 론: 국소진행성 비소세포폐암환자에서 gemcitabine $500\;mg/m^2$과 cisplatin $30\;mg/m^2$의 2주 간격 투여와 동시 항암화학방사선치료는 높은 치료반응률을 나타내었다. 그러나 3도 이상의 식도염과 폐렴이 예상보다 많이 관찰되어 이에 대한 부작용을 줄이기 위한 적절한 방법들이 강구되어야 할 것이며, 항암제의 용량조절, 방사선조사량의 조절과 특수 방사선치료방법들의 개발이 필요하리라고 판단되었다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권11호
• /
• pp.6883-6888
• /
• 2013

Background: Platinum based concurrent chemo-radiation is the de-facto standard of care in the non-surgical management of locally-advanced head and neck cancer of squamous origin. Three-weekly single agent cisplatin at 100 $mg/m^2$ concurrent with radical radiotherapy has demonstrated consistent improvement in loco-regional control and survival. This improvement is however at the cost of considerable hematologic toxicity and poor overall compliance. The routine use of this regime is improbable in developing countries with limited resources. We therefore aimed to determine the safety and efficacy of an alternative regime of weekly cisplatin and concurrent radiotherapy in such patients. Materials and Methods: January-05 and April-12, 188 patients of locally-advanced head and neck cancer of squamous origin were treated with concurrent weekly-cisplatin at $35mg/m^2$ and conventional radiotherapy 60-66Gy/30-33 fractions/5days per week. Results: Overall, 95% patients received planned doses of RT while 74% completed within the stipulated overall treatment time of <50 days. Eighty-two percent received at-least 5 weekly cycles. Grade-III/IV mucositis was seen in 58%/9% respectively, which resulted in mean weight loss of 9.2% from a pre-treatment mean of 54.5 kg. Grade-III hematologic toxicity-0.5%; grade II nephrotoxicity-2.5% and grade III emesis-3% were also seen. Grade-III/IV subcutaneous toxicity-10%/1% and grade-III/IV xerostomia-10%/0% were observed. Complete responses at the primary site, regional nodes and overall disease were seen in 86%, 89% and 83% patients respectively. The median and 5-years disease-free survival were 26 months and 39.4% respectively, while the median and overall survival were 27 months and 41.8% respectively. Conclusions: Weekly-cisplatin at 35 $mg/m^2$ when delivered concurrently with conventional radical RT (at-least 66y/33 fractions) in locally-advanced head and neck cancer is well tolerated with minimal hematologic and neprologic toxicity and can be routinely delivered on an out-patient basis. It is an effective alternative to the standard 3-weekly cisplatin especially in the context of developing countries.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권6호
• /
• pp.2793-2796
• /
• 2014

Background: Glioblastoma multiform (GBM) is a highly aggressive tumor with median survival of approximately 14 months. Management consists of maximal surgical resection followed by post-operative chemoradiation with concurrent then adjuvant temozolamide. The standard radiotherapy dose is 60Gy in 2-Gy fractions recommended by the radiation therapy oncology group (RTOG). With the vast majority of tumor recurrences occurring within the previous irradiation field and the poor outcome associated with standard therapy, regimens designed to deliver higher radiation doses to improve local control and enhance survival are needed. In this study, we report a single institutional experience in treatment of 68 consecutive patients with GBM, treated with resection, and given post-operative radiotherapy followed by concurrent and/or adjuvant chemotherapy. Results: Of the 80 patients who entered this study, 68 completed the treatment course; 45 (66.2%) males and 23 (33.8%) females with a mean age at diagnosis of $49.0{\pm}12.9$ (21-75) years. At a median follow up of 19 months, 39 (57.3%) patients had evidence of tumor progression and 36 (52.9%) had died. The median over all survival for all patients was 16 months and progression free survival for all patients was 6.02 months. All potential prognostic factors were analyzed to evaluate their effects on overall survival. Age ${\leq}50$ year, concurrent and adjuvant chemotherapy and extent of surgery had significant p values. We found lower progression rate among patients who received higher doses of radiotherapy (>60Gy). Higher radiation doses improved progression free survival (p=0.03). Despite increasing overall survival, this elevation was not significant. Conclusions: This study emphasize that higher radiation doses of (>60Gy) can improve local control and potentially survival, so we strongly advise prospective multi centric studies to evaluate the role of higher doses of radiotherapy on GBM patient outcome.